Yungan Tao, President-Elect of GORTEC and Radiation Oncologist of Head and Neck Cancer at Gustave-Roussy Institute, shared a post on X about a paper he co-authored with colleagues published in The Lancet:
“Excited to share the final publication in The Lancet of our phase 3 GORTEC 2018-01 (NIVOPOST-OP) trial results. We hope these results will support changes in clinical practice and future guideline updates.”
Title: Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial
Authors: Jean Bourhis, Anne Aupérin, Christian Borel, Gautier Lefebvre, Severine Racadot, Lionnel Geoffrois, Xu Shan Sun, Esma Saada, Beatriz Cirauqui, Tomasz Rutkowski, Stephanie Henry, Anouchka Modesto, Alison Johnson, Sophie Chapet, Benoit Calderon, Christian Sire, Olivier Malard, Matthieu Bainaud, Antonio Da Silva Motta, Sebastien Thureau, Yoann Pointreau, Pierre Blanchard, Guillaume Buiret, Laurence Bozec, Stephane Lopez, Julie Vanbockstael, Matthieu Bosset, Charlotte Greilsamer, Amaury Daste, Antoine Bruna, France N’Guyen, Maria Plana, Eluska Iruarrizaga, Stephane Temam, Caroline Even, Elisabeth Perez Ruiz, Mahasti Bert, Eleni Karamouza, Juliette Thariat, Joanna Kazmierska, Amanda Psyrri, Ricard Mesia, and Yungan Tao.
You can read the Full Article in The Lancet.
More posts featuring Yungan Tao.